Clinical Trials in Detroit

Showing 7861-7880 of 14,997 trials

Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT02715011

The purpose of this study is to characterize the safety and tolerability of JNJ-63709178 and identify the recommended Phase 2 dose(s) (RP2D) and schedule for JNJ-63709178 in Part 1 and to characterize the safety and tolerability of JNJ-63709178 at the RP2D(s) in Part 2.

Leukemia, Myeloid, Acute

Janssen Research & Development, LLC62 participantsStarted Jun 2016

Detroit, Michigan, United States • New York, New York, United States • Charlotte, North Carolina, United States +7 more locations

COMPLETEDPhase 1< 1 mile

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

NCT02655822

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Renal Cell CancerMetastatic Castration Resistant Prostate Cancer

Corvus Pharmaceuticals, Inc.502 participantsStarted Jan 2016

Tucson, Arizona, United States • San Francisco, California, United States • Stanford, California, United States +17 more locations

Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Find Trials by Condition in Detroit

Aerosolized Surfactant in Neonatal RDS

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)

Evaluation of a Neck Strengthening Program to Reduce the Risk of Sport-related Concussion

St.Jude Medical Cardiac Lead Assessment Study

PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases

Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis

Clinical Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) Utilizing Vaginal Swabs

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor